Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

CSPC Pharmaceutical Group

Status and phase

Terminated

Phase 2

Conditions

Relapsed Cutaneous T Cell Lymphom

Treatments

Drug: Mitoxantrone HCL Liposome Injection

Study type

Interventional

Funder types

Industry

Identifiers

CSPC-HE154/PRO/Ⅱ

Details and patient eligibility

About

To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed cutaneous T cell lymphomasell

Enrollment

1 patient

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The subjects are voluntary and sign the informed consent form;
ECOG score 0 to 2;
The expected survival time ≥3 months;
Patients with cutaneous T-cell lymphoma confirmed by histopathology, with measurable lesions, with or without systemic lymph node involvement; clinical stage IB-IVA;
The patients previously receive at least once of systemic therapy (including systemic electron beam irradiation or chemotherapy, stem cell transplantation) and do not achieve remission (including remission period shorter than 30 days after the treatment;
An interval of at least four weeks after the target tumor was treated with chemotherapy, radiotherapy, biological therapy, stem cell transplantation or other study drugs;
Subjects at childbearing age agree to take effective contraceptive measures during the study; blood pregnancy test result is negative (except infertility due to menopause or operation);
Laboratory tests (blood routine, liver and kidney function) meet the following requirements:
1. ANC≥ 1.5×109/L; b) PLT ≥ 75×109/L; c) Hb ≥ 9 g/dL; d) Cr) ≤ 1.5x ULN ; e) TBIL ≤ 1.5x ULN; f) AST or ALT ≤2.5 x ULN.

Exclusion criteria

Pregnant or lactating women;
An allergic history to anthracyclines or liposome drugs;
Disease progression or recurrence after anthracycline treatment within six months before the enrollment;"
Patients who once used mitoxantrone injection;
Patients who have used doxorubicin (or pirarubicin) with the total cumulative dose> 360mg/m2, or epirubicin with the total cumulative dose > 600mg/m2;
Left ventricular ejection fraction is < 50% or < the lower limit of normal; clinically significant QT interval prolongation (>450ms in male, >470ms in female); a past history of cardiac disease caused by anthracyclines; a history of severe heart disease;
Concomitant treatment as other anticancer drugs are needed;
With internal organ involvement (including bone marrow, central nervous system;
Clinically active infection that can significantly affect the clinical trial;
Within 6 weeks after organ transplantation or major organ surgery;
Those who are inappropriate to be enrolled as evaluated by the researchers.